Therapeutic Efficacy and Mechanisms of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Ocular Graft-Versus-Host Disease DOI Creative Commons

C. Ye,

Shuwan Liu, Jing Hong

et al.

Cornea, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

To provide a comprehensive overview of the clinical manifestations, pathophysiology, and current treatments ocular graft-versus-host disease (oGVHD), to explore therapeutic potential mesenchymal stem cells (MSCs) their exosomes (MSC-Exos) as novel treatments. A literature review was conducted using major databases (PubMed, Web Science, Scopus) identify studies published between 2000 2024. The focus on trials, case series, experimental related oGVHD. Data were synthesized summarize knowledge. oGVHD affects 40% 60% Hematopoietic Stem Cell Transplantation recipients, causing symptoms such dryness, irritation, vision impairment. Current often fail long-term relief may cause significant side effects. MSCs MSC-Exos offer promising alternative because immunosuppressive regenerative properties. Preclinical have demonstrated safety efficacy in improving promoting corneal health. show promise treating oGVHD, with improve promote tissue repair. Further research is needed establish efficacy.

Language: Английский

Therapeutic Efficacy and Mechanisms of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Ocular Graft-Versus-Host Disease DOI Creative Commons

C. Ye,

Shuwan Liu, Jing Hong

et al.

Cornea, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

To provide a comprehensive overview of the clinical manifestations, pathophysiology, and current treatments ocular graft-versus-host disease (oGVHD), to explore therapeutic potential mesenchymal stem cells (MSCs) their exosomes (MSC-Exos) as novel treatments. A literature review was conducted using major databases (PubMed, Web Science, Scopus) identify studies published between 2000 2024. The focus on trials, case series, experimental related oGVHD. Data were synthesized summarize knowledge. oGVHD affects 40% 60% Hematopoietic Stem Cell Transplantation recipients, causing symptoms such dryness, irritation, vision impairment. Current often fail long-term relief may cause significant side effects. MSCs MSC-Exos offer promising alternative because immunosuppressive regenerative properties. Preclinical have demonstrated safety efficacy in improving promoting corneal health. show promise treating oGVHD, with improve promote tissue repair. Further research is needed establish efficacy.

Language: Английский

Citations

0